Stock Research for ALXN

ALXN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ALXN Stock Chart & Research Data

The ALXN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALXN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ALXN Due diligence Resources & Stock Charts

The ALXN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ALXN Detailed Price Forecast - CNN Money CNN View ALXN Detailed Summary - Google Finance
Yahoo View ALXN Detailed Summary - Yahoo! Finance Zacks View ALXN Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ALXN Trends & Analysis - Trade-Ideas Barrons View ALXN Major Holders - Barrons
NASDAQ View ALXN Call Transcripts - NASDAQ Seeking View ALXN Breaking News & Analysis - Seeking Alpha
Spotlight View ALXN Annual Report - CompanySpotlight.com OTC Report View ALXN OTC Short Report - OTCShortReport.com
TradeKing View ALXN Fundamentals - TradeKing Charts View ALXN SEC Filings - Bar Chart
WSJ View Historical Prices for ALXN - The WSJ Morningstar View Performance/Total Return for ALXN - Morningstar
MarketWatch View the Analyst Estimates for ALXN - MarketWatch CNBC View the Earnings History for ALXN - CNBC
StockMarketWatch View the ALXN Earnings - StockMarketWatch MacroAxis View ALXN Buy or Sell Recommendations - MacroAxis
Bullish View the ALXN Bullish Patterns - American Bulls Short Pains View ALXN Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ALXN Stock Mentions - StockTwits PennyStocks View ALXN Stock Mentions - PennyStockTweets
Twitter View ALXN Stock Mentions - Twitter Invest Hub View ALXN Investment Forum News - Investor Hub
Yahoo View ALXN Stock Mentions - Yahoo! Message Board Seeking Alpha View ALXN Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for ALXN - SECform4.com Insider Cow View Insider Transactions for ALXN - Insider Cow
CNBC View ALXN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ALXN - OTC Markets
Yahoo View Insider Transactions for ALXN - Yahoo! Finance NASDAQ View Institutional Holdings for ALXN - NASDAQ


Stock Charts

FinViz View ALXN Stock Insight & Charts - FinViz.com StockCharts View ALXN Investment Charts - StockCharts.com
BarChart View ALXN Stock Overview & Charts - BarChart Trading View View ALXN User Generated Charts - Trading View


Latest Financial News for ALXN

Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash
Posted on Wednesday June 20, 2018

The biotech sector showed volatility with a few companies gaining on positive data readouts while a few plunging on dismal results.


5 Stocks That Are Screaming Buys Right Now
Posted on Wednesday June 20, 2018

Here we used TipRanks' stock screener to pinpoint the most compelling stocks right now. The Street is buzzing about Neurocrine's Ingrezza drug, the first FDA-approved treatment for adults with tardive dyskinesia. On its first quarter earnings call, Neurocrine updated the Street with respect to ongoing market penetration for Ingrezza.


Future home of PTC, Alexion could sell for $450M
Posted on Wednesday June 20, 2018

The 17-story office at 121 Seaport Blvd. will be the future headquarters of industrial software company PTC, which is relocating from Needham, and Alexion Pharmaceuticals, which is relocating from New Haven, Connecticut.


Why This Biotech Company Could Shock 2019 Sales Expectations
Posted on Tuesday June 19, 2018

Alexion surprised Wall Street on Tuesday when it asked the FDA for an expedited review of its newest rare-disease drug, ALXN1210.


Enter a stock symbol to view the stock details.